Chen H H, Tabar L, Fagerberg G, Duffy S W
Department of Community Medicine, University of Cambridge, United Kingdom.
J Med Screen. 1995;2(1):10-4. doi: 10.1177/096914139500200104.
To assess the effect of mammographic screening for breast cancer in women aged 65 years or over.
The Swedish two county trial of screening for breast cancer, in which 77,080 women aged 40-74 (21,925 aged 65-74) were randomly allocated to receive regular mammographic screening for breast cancer, and 55,985 women aged 40-74 (15,344 aged 65-74) were allocated to an unscreened control group.
One group was screened every 33 months on average, except for those aged 40-49 at randomisation who were screened every 24 months. The control group was screened once at the conclusion of the trial. The main statistical analysis was the comparison of cumulative mortality with 13 years of follow up between the screened and control groups, in age groups 50-64 and 65-74, using Poisson regression. This was complemented by subsidiary analyses assessing the lead time, sensitivity, and predicted mortality from the size, node status, and grade of tumours diagnosed in the screened and control groups.
In the age group 65-74 at randomisation there was a significant reduction in breast cancer mortality in the screened group, with a relative mortality of 0.68 and 95% confidence interval of 0.51 to 0.89. This was backed up by the results of the analyses of lead time, sensitivity, and tumour characteristics.
Women aged 65 or more who are regularly screened can expect a reduced risk of dying from breast cancer.
评估乳腺钼靶筛查对65岁及以上女性乳腺癌的影响。
瑞典两县乳腺癌筛查试验,其中77080名年龄在40 - 74岁(21925名年龄在65 - 74岁)的女性被随机分配接受定期乳腺钼靶乳腺癌筛查,55985名年龄在40 - 74岁(15344名年龄在65 - 74岁)的女性被分配到未筛查的对照组。
一组平均每33个月筛查一次,随机分组时年龄在40 - 49岁的女性每24个月筛查一次。对照组在试验结束时筛查一次。主要统计分析是使用泊松回归比较筛查组和对照组在50 - 64岁和65 - 74岁年龄组中13年随访期的累积死亡率。通过辅助分析评估筛查组和对照组中诊断出的肿瘤大小、淋巴结状态和分级的提前期、敏感性和预测死亡率来补充分析。
在随机分组时年龄在65 - 74岁的年龄组中,筛查组乳腺癌死亡率显著降低,相对死亡率为0.68,95%置信区间为0.51至0.89。提前期、敏感性和肿瘤特征的分析结果支持了这一点。
定期接受筛查的65岁及以上女性死于乳腺癌的风险有望降低。